Bavarian Nordic A/S (BVNKF)
BVNKF Stock Price Chart
Explore Bavarian Nordic A/S interactive price chart. Choose custom timeframes to analyze BVNKF price movements and trends.
BVNKF Company Profile
Discover essential business fundamentals and corporate details for Bavarian Nordic A/S (BVNKF) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
15 Oct 2010
Employees
1.65K
Website
https://www.bavarian-nordic.comCEO
Paul John Chaplin MSc,
Description
Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN (freeze-dried) that has completed Phase III clinical trials for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that has completed Phase II clinical trial for the treatment of SARS-CoV-2; and TAEK-VAC, which is in Phase I/II clinical trial for treatment of advanced HER2 and brachyury-expressing cancers. It has license and collaboration agreement with AdaptVac; and license agreements with National Cancer Institute and Public Health Service. The company operates in the United States, Belgium, Germany, the Netherlands, Sweden, Switzerland, Austria, the United Kingdom, Japan, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.
BVNKF Financial Timeline
Browse a chronological timeline of Bavarian Nordic A/S corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 7 May 2026
Upcoming earnings on 3 Mar 2026
Upcoming earnings on 14 Nov 2025
Earnings released on 22 Aug 2025
EPS came in at $0.43 falling short of the estimated $1.90 by -77.59%, while revenue for the quarter reached $227.68M , missing expectations by -86.42%.
Earnings released on 8 May 2025
EPS came in at $0.40 , while revenue for the quarter reached $198.19M , beating expectations by +37.70%.
Earnings released on 5 Mar 2025
EPS came in at $1.35 surpassing the estimated $1.18 by +14.41%, while revenue for the quarter reached $289.79M , beating expectations by +11.85%.
Earnings released on 15 Nov 2024
EPS came in at $0.90 falling short of the estimated $4.00 by -77.50%, while revenue for the quarter reached $200.60M , missing expectations by -90.50%.
Earnings released on 22 Aug 2024
EPS came in at $0.48 surpassing the estimated $0.28 by +72.74%, while revenue for the quarter reached $205.55M , beating expectations by +10.45%.
Earnings released on 8 May 2024
EPS came in at -$1.50 falling short of the estimated $1.90 by -178.95%, while revenue for the quarter reached $119.40M , missing expectations by -24.91%.
Earnings released on 6 Mar 2024
EPS came in at $11.70 surpassing the estimated $7.80 by +50.00%, while revenue for the quarter reached $361.46M , beating expectations by +73.28%.
Earnings released on 16 Nov 2023
EPS came in at -$4.40 falling short of the estimated $6.43 by -168.43%, while revenue for the quarter reached $194.21M , missing expectations by -22.68%.
Earnings released on 23 Aug 2023
EPS came in at $7.10 surpassing the estimated $3.95 by +79.75%, while revenue for the quarter reached $290.23M , beating expectations by +14.60%.
Earnings released on 9 May 2023
EPS came in at $5.10 surpassing the estimated $2.38 by +114.29%, while revenue for the quarter reached $182.53M , missing expectations by -14.36%.
Earnings released on 2 Mar 2023
EPS came in at $2.20 falling short of the estimated $3.30 by -33.33%, while revenue for the quarter reached $186.39M , beating expectations by +2.89%.
Earnings released on 9 Nov 2022
EPS came in at $0.20 surpassing the estimated -$0.25 by +180.00%, while revenue for the quarter reached $131.53M , missing expectations by -0.85%.
Earnings released on 24 Aug 2022
EPS came in at -$3.40 surpassing the estimated -$3.80 by +10.53%, while revenue for the quarter reached $75.36M , beating expectations by +4.57%.
Earnings released on 9 May 2022
EPS came in at -$3.90 surpassing the estimated -$4.70 by +17.02%, while revenue for the quarter reached $47.60M , missing expectations by -11.75%.
Earnings released on 4 Mar 2022
EPS came in at -$1.60 falling short of the estimated $0.45 by -455.56%, while revenue for the quarter reached $82.91M , missing expectations by -2.56%.
Earnings released on 12 Nov 2021
EPS came in at -$1.30 falling short of the estimated -$1.15 by -13.04%, while revenue for the quarter reached $70.00M , missing expectations by -10.54%.
Earnings released on 25 Aug 2021
EPS came in at -$2.40 falling short of the estimated $0.95 by -352.63%, while revenue for the quarter reached $58.98M .
Earnings released on 27 May 2021
EPS came in at -$2.20 falling short of the estimated -$1.45 by -51.72%, while revenue for the quarter reached $84.56M .
Earnings released on 28 Jan 2021
EPS came in at -$7.30 falling short of the estimated -$3.18 by -129.56%, while revenue for the quarter reached $37.59M .
Earnings released on 11 Nov 2020
EPS came in at $0.50 surpassing the estimated $0.38 by +31.58%, while revenue for the quarter reached $88.02M .
BVNKF Stock Performance
Access detailed BVNKF performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.